Trial Profile
A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083) in Growth Hormone deficient adults (AGHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novo Nordisk
- 26 Mar 2014 New trial record